
Zealand Pharma, a biotech firm publicly listed in Denmark that has been undergoing comprehensive structural changes since March, announced on Tuesday that it has sold its insulin pump, dubbed V-Go, to US-based firm Mannkind Corporation.
Under the terms of the deal, Zealand Pharma receives an upfront USD 10m payment in addition to undisclosed sales-based milestones.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app